Age-stratified analysis of COVID-19 severity outcomes among vaccinees and individuals with prior SARS-CoV-2 exposure in Indiana FSPH_IU COVID19 SARSCoV2 COVID19 Indiana Analysis
By Pooja Toshniwal PahariaDec 21 2022Reviewed by Aimee Molineux In a recent study published in the American Journal of Public Health, researchers assessed the effectiveness of vaccine-conferred immune protection against novel severe acute respiratory syndrome coronavirus 2 infections, any-cause visits to hospitals and emergency departments , and deaths in Indiana.
The team leveraged population health vaccination data and electronic medical records from the INPC and the Indiana vaccination registry to match individuals who had been administered ≥1.0 dose of COVID-19 vaccines with individuals having prior COVID-19 history. The study participants were matched for index dates, sex, age, ethnicity/race, postal codes, clinical diagnosis, and comorbidities identified by the CDC to be a suggestive or conclusive risk factor for severe SARS-CoV-2 infections.
Results Related StoriesA total of 736,193 previously infected individuals and 2,798,709 previously vaccinated individuals were identified from the INPC between 29 November 2020 and 9 February 2022, from which 267,847 matched individual pairs were obtained. After six months of index dates, COVID-19 incidence was significantly greater among vaccinees than individuals with prior COVID-19 history . Any-cause deaths among vaccinees, however, were 37.
Among adult individuals aged between 20 and 39 years, at six months, the incidence rates of SARS-CoV-2 infections were greater among vaccinees than previously infected individuals at six months. However, the incidence rate of any-cause ED visits was greater among previously infected individuals compared to previously vaccinated individuals . Likewise, at 6.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Milk antibodies against SARS-CoV-2 after booster vaccination and breakthrough infectionMilk antibodies against SARS-CoV-2 after booster vaccination and breakthrough infection medrxivpreprint UCSF SARSCoV2 COVID19 Booster Vaccine Vaccination
Lire la suite »
What is the impact of cholesterol on SARS-CoV-2 Spike protein-mediated membrane fusion?Researchers assessed the impact of ceramide (CER) and cholesterol (CHOL) on membrane fusion mediated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
Lire la suite »
SARS-CoV-2 structural proteins trigger periodontal fibrosisResearchers examined the pathological impacts of the structural components of SARS-CoV-2 on human periodontal cells and tissue to understand the association between coronavirus disease 2019 (COVID-19) and deteriorating oral health.
Lire la suite »
The potential effects of receiving 2 SARS-CoV-2 vaccine doses on household transmission in EnglandThe potential effects of receiving 2 SARS-CoV-2 vaccine doses on household transmission in England CDCgov ucl SARSCoV2 vaccine vaccination transmission covid coronavirus covid
Lire la suite »
Study finds increased risk of POTS after SARS-CoV-2 infection or COVID vaccinationStudy finds increased risk of POTS after SARS-CoV-2 infection or COVID vaccination Coronavirus Disease COVID SARSCoV2 tachycardia NatureCVR karolinskainst UBuffalo
Lire la suite »
Exploring environmental viral emissions after SARS-CoV-2 Human challengeA recent study captured the dynamics of pre-symptomatic SARS-CoV-2 emissions and reported the extent, magnitude, and routes of viral transmission are heterogeneous, with nasal mucosa being an important source of viral transmission.
Lire la suite »